PL2999475T3 - Imidazolowi antagoniści progesteronu - Google Patents

Imidazolowi antagoniści progesteronu

Info

Publication number
PL2999475T3
PL2999475T3 PL14807137T PL14807137T PL2999475T3 PL 2999475 T3 PL2999475 T3 PL 2999475T3 PL 14807137 T PL14807137 T PL 14807137T PL 14807137 T PL14807137 T PL 14807137T PL 2999475 T3 PL2999475 T3 PL 2999475T3
Authority
PL
Poland
Prior art keywords
imidazolyl
progesterone antagonists
progesterone
antagonists
imidazolyl progesterone
Prior art date
Application number
PL14807137T
Other languages
English (en)
Inventor
Klaus Nickisch
Walter Elger
Bindu Santhamma
Original Assignee
Evestra, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evestra, Inc. filed Critical Evestra, Inc.
Publication of PL2999475T3 publication Critical patent/PL2999475T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
PL14807137T 2013-06-05 2014-06-05 Imidazolowi antagoniści progesteronu PL2999475T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/910,273 US9096641B2 (en) 2013-06-05 2013-06-05 Imidazolyl progesterone antagonists
EP14807137.6A EP2999475B1 (en) 2013-06-05 2014-06-05 Imidazolyl progesterone antagonists
PCT/US2014/041002 WO2014197653A2 (en) 2013-06-05 2014-06-05 Imidazolyl progesterone antagonists

Publications (1)

Publication Number Publication Date
PL2999475T3 true PL2999475T3 (pl) 2019-08-30

Family

ID=52005991

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14807137T PL2999475T3 (pl) 2013-06-05 2014-06-05 Imidazolowi antagoniści progesteronu

Country Status (14)

Country Link
US (1) US9096641B2 (pl)
EP (1) EP2999475B1 (pl)
JP (1) JP2016520649A (pl)
KR (1) KR20160051693A (pl)
CN (1) CN105530943B (pl)
AU (1) AU2014274930B2 (pl)
BR (1) BR112015030308A2 (pl)
CA (1) CA2917031C (pl)
ES (1) ES2683446T3 (pl)
HU (1) HUE041548T2 (pl)
MX (1) MX364985B (pl)
PL (1) PL2999475T3 (pl)
RU (1) RU2679445C2 (pl)
WO (1) WO2014197653A2 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113559075A (zh) 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
CA2998924A1 (en) 2015-09-25 2017-03-30 Context Biopharma Inc. Methods of making onapristone intermediates
JP2019503353A (ja) 2015-12-15 2019-02-07 コンテキスト・バイオファーマ・インコーポレイテッド 非晶質オナプリストン組成物およびそれを作製する方法
US11124537B2 (en) 2015-12-23 2021-09-21 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
AU2016379417B2 (en) 2015-12-23 2020-09-24 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
JP2019513706A (ja) * 2016-03-21 2019-05-30 コンテキスト・バイオファーマ・インコーポレイテッド オナプリストン代謝物質組成物及び方法
PT3523315T (pt) * 2016-10-07 2021-04-29 Oric Pharmaceuticals Inc Inibidor de recetor de glucocorticoide
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
WO2021163273A1 (en) * 2020-02-12 2021-08-19 Oric Pharmaceuticals, Inc. Uses of glucocorticoid receptor antagonists

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2573657B1 (fr) * 1984-11-29 1989-05-12 Roussel Uclaf Produit comprenant une substance antiprogestomimetique et une substance uterotonique
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
ES2045082T3 (es) 1987-04-24 1994-01-16 Akzo Nv Un metodo para la preparacion de nuevos derivados 11-arilestrano y 11-arilpregnano.
DE3822770A1 (de) 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
FR2651435A1 (fr) 1989-09-07 1991-03-08 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques.
ZA929315B (en) 1991-12-20 1993-05-24 Akzo Nv 17-spirofuran-3'-ylidene steroids.
FR2688004A1 (fr) 1992-02-27 1993-09-03 Roussel Uclaf Nouveaux sterouides comportant en position 17 un radical methylene lactone, leur procede et des intermediaires de preparation, leur application comme medicaments.
CA2100514C (en) * 1992-07-29 2005-03-29 Johannes A. M. Hamersma 17-spiromethylene steroids
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
IL119649A (en) 1995-11-30 2002-03-10 Akzo Nobel Nv Preparation of Cyclic Kills of History - 3 keto- (5) 10, (-9) 11 steroidadians
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6262042B1 (en) * 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US5962444A (en) * 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6172052B1 (en) * 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
CA2394731C (en) 1999-12-29 2008-08-26 Hyun Koo Kim Process for preparing 17alpha-acetoxy-11beta-[4-n,n-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for preparing such intermediates
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
US8673968B2 (en) 2009-04-06 2014-03-18 Evestra, Inc. Progesterone antagonists
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) * 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
US20130029953A1 (en) 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists

Also Published As

Publication number Publication date
EP2999475A2 (en) 2016-03-30
AU2014274930B2 (en) 2018-11-08
US9096641B2 (en) 2015-08-04
RU2015156415A3 (pl) 2018-03-27
CN105530943A (zh) 2016-04-27
BR112015030308A2 (pt) 2017-07-25
KR20160051693A (ko) 2016-05-11
CN105530943B (zh) 2018-11-16
WO2014197653A3 (en) 2015-04-30
HUE041548T2 (hu) 2019-05-28
JP2016520649A (ja) 2016-07-14
EP2999475A4 (en) 2017-02-15
EP2999475B1 (en) 2018-07-25
ES2683446T3 (es) 2018-09-26
CA2917031A1 (en) 2014-12-11
MX364985B (es) 2019-05-09
CA2917031C (en) 2021-12-07
AU2014274930A1 (en) 2016-01-28
RU2015156415A (ru) 2017-07-14
WO2014197653A2 (en) 2014-12-11
US20140364600A1 (en) 2014-12-11
MX2015016550A (es) 2016-12-12
RU2679445C2 (ru) 2019-02-11

Similar Documents

Publication Publication Date Title
SG11201510157YA (en) T cell receptors
ZA201600959B (en) T cell receptors
IL240404A0 (en) link means
PL2999475T3 (pl) Imidazolowi antagoniści progesteronu
ZA201604490B (en) S1p3 antagonists
EP2980873A4 (en) CRYOSTAT
HUP1300139A2 (en) Phenoxypiperidine h3 antagonists
PL2992225T3 (pl) Łącznik
GB201322430D0 (en) T cell receptors
GB201305118D0 (en) Blends
PT3051152T (pt) Estrutura de ligação para peças de madeira
GB201321332D0 (en) Fitting
GB2521337B (en) Test fitment
PL2941313T3 (pl) Urządzenie łączące
TWM477084U (en) Connecting device
AU353373S (en) Connecting device
AU353374S (en) Connecting device
AU353372S (en) Connecting device
AU353267S (en) Connecting device
AU353266S (en) Connecting device
AU353213S (en) Connecting device
AU351764S (en) Connecting device
AU351589S (en) Connecting device
GB201322666D0 (en) Fitting
GB201301988D0 (en) Motorhome